Core Viewpoint - Euroseas Ltd. has secured a new time charter contract for its intermediate containership, M/V Emmanuel P, at a gross daily rate of $38,000 for a period of 36 to 38 months, reflecting the strength of the containership market and increasing future cash flow visibility [1][2]. Company Summary - Euroseas Ltd. operates in the container shipping market, managing a fleet of 22 vessels, including 15 feeder containerships and 7 intermediate containerships, with a total cargo capacity of 67,494 teu [7]. - The company is expected to generate over $32 million in EBITDA from the new charter contract, increasing charter coverage to approximately 97% for 2025, 67% for 2026, and 40% for 2027 [2]. - The average contracted daily rate for the company will rise to about $28,700 for the remainder of 2025, over $31,000 in 2026, and over $33,000 in 2027 [2]. Fleet Profile - After the new charter of M/V Emmanuel P, the fleet profile includes various intermediate and feeder containerships with different TCE rates, highlighting the company's diverse operational capabilities [3][4]. - The M/V Emmanuel P, built in 2005, will transition from a previous charter rate of $21,000 to the new rate of $38,000 upon completion of scheduled drydock and energy-saving device installations [1][3]. Future Outlook - Euroseas is set to expand its fleet to 23 vessels with a total carrying capacity of 69,744 teu after the delivery of two new intermediate containerships in 2027 [7]. - The company’s operations are managed by Eurobulk Ltd., which is responsible for the day-to-day commercial and technical management of the vessels [6].

TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- (TSX: MPY) Mulvihill Premium Yield Fund has declared a monthly cash distribution for its ETF Class in the amount of $0.06400 per unit, payable on July 7, 2025 to unitholders of record on June 30, 2025. For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com. John Germain, Senior Vice-President & CFOMulvihill Capital Management Inc.121 King Street WestSuite 2600To ...

Core Insights - Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors [3] - The company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025 [1] Company Overview - Bicara Therapeutics is dedicated to creating transformative bifunctional therapies, with its lead program being ficerafusp alfa, a first-in-class bifunctional antibody [3] - Ficerafusp alfa targets the tumor microenvironment by combining an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) [3] - The therapy aims to reverse the fibrotic and immune-excluded tumor microenvironment, facilitating deeper tumor penetration and promoting durable responses [3] - Ficerafusp alfa is currently being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [3]

VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025. Fireside Chat Presentation Details: Date:Tuesday, June 10, 2025 Time:3:20-3:55 PM Eas ...

Core Points - Current Water Technologies Inc. has successfully closed a private placement raising a total of $209,450 CAD [1][2] - The company issued 6,981,667 units at a price of $0.03 per unit, with each unit consisting of one Common Share and one Share Purchase Warrant [2] - Each Warrant allows the holder to purchase one Common Share at an exercise price of $0.06, exercisable for three years from the closing date [2] Private Placement Details - The private placement was conducted under the minimum price exception within Policy 1.1 of the TSXV Corporate Manual, allowing issuance at the market price with a minimum of $0.01 [3] - No finder's fees were paid in connection with the private placement [2] - Gene Shelp, the CEO, participated in the private placement by acquiring 1,315,000 units and warrants, which are considered related party transactions [4] Insider Participation - The participation of insiders did not materially change the percentage of outstanding securities owned by them, and the company is exempt from formal valuation and minority shareholder approval requirements [4] - The common shares issued to insiders are subject to a four-month hold period as per TSX-V policies [4] Company Overview - Current Water Technologies is a technology company specializing in patented electrochemical technologies for wastewater treatment, desalination, and drinking water purification [5] - The company operates in sectors including mining, metal processing, chemical, agricultural, municipal, and waste management [5] - Pumptronics Incorporated, a division of the company, focuses on custom design and automation of integrated pump stations [5] Trading Information - The common shares of Current Water Technologies trade on Tier II of the TSX Venture Exchange under the symbol "WATR" [6]

Flight utilized BETA’s ALIA CTOL, which departed East Hampton Airport, New York and arrived at John F. Kennedy International Airport in New York CityBlade CEO Rob Wiesenthal's participation as a passenger on the all-electric flight underscores the company’s commitment to quiet, emission-free air mobilityBlade, BETA Technologies, and other Advanced Air Mobility manufacturers continue to collaborate on the integration of Electric Vertical Aircraft (“EVA” or “eVTOL”) in Blade’s service model NEW YORK, June 03, ...

Core Insights - Immix Biopharma's NXC-201 achieved a complete response (CR) rate of 70% in the NEXICART-2 Phase 1/2 clinical trial for relapsed/refractory AL Amyloidosis, meeting its primary endpoint [1][4][3] - The trial reported no relapses or safety signals to date, indicating a favorable safety profile for NXC-201 [1][4] - Immix plans to submit a Biologics License Application (BLA) to the FDA for NXC-201 following these promising results [1][3] Clinical Trial Details - The NEXICART-2 trial is a U.S. multi-site, single-arm study evaluating NXC-201 in patients with relapsed/refractory AL Amyloidosis, with a data cutoff of April 11, 2025 [1][3][7] - Prior to treatment, patients had a median of 4 lines of therapy, and all had organ involvement from the disease [4] - After treatment, all patients normalized pathological disease markers, with 70% achieving complete responses [4] Safety and Efficacy - No neurotoxicity was observed, and only low-grade cytokine release syndrome was reported [4][9] - The remaining 3 patients who did not achieve CR are minimum residual disease (MRD) negative, suggesting potential future CRs [4] Market Context - Current treatments for relapsed/refractory AL Amyloidosis have a CR rate of less than 10%, highlighting a significant unmet medical need [5] - The U.S. prevalence of relapsed/refractory AL Amyloidosis is estimated to grow at 12% per year, reaching approximately 33,277 patients by 2024 [11] - The amyloidosis market was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025 [11] Company Overview - Immix Biopharma is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [12] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation from both the FDA and EMA [9][12]

Core Points - Colabor Group Inc. has completed the acquisition of food distribution assets from Alimplus Inc. and all shares of Tout-Prêt Inc. for a revised total consideration of $49.75 million [1] - The acquisition includes assets related to food distribution and the shares of Tout-Prêt, which specializes in cut fruits and vegetables distribution in Quebec, with expected annual sales of approximately $225 million [2] - Colabor has entered into a distribution agreement with Groupe Mayrand Alimentation inc. for an initial six-year term, although their four stores are not part of the acquisition [2] Financing Details - The company has amended and restated its senior first-ranking secured credit facility, extending the maturity date to June 2029, with a total amount of $91.75 million [5] - The credit facility consists of a $50 million revolving credit and a $41.75 million term loan [5] - Colabor has also secured an agreement with Investissement Québec to extend its existing $15 million subordinated debt maturing in December 2029 and entered into a new financing agreement for an additional $15 million in highly subordinated debt with a 5-year term [5]

Group 1 - EssilorLuxottica successfully launched a bond issuance totaling Euro 1 billion, maturing in January 2030, with a coupon of 2.625% and a yield of 2.76% [4] - The bond issuance attracted significant interest, with the order book peaking over Euro 2.5 billion, indicating strong confidence from institutional investors in EssilorLuxottica's business model and credit profile [4] - The proceeds from the bond issuance will be utilized for general corporate purposes, with trading on Euronext Paris expected to commence on June 10, 2025 [5] Group 2 - The bonds were offered exclusively to qualified investors as defined by MiFID II, and are not available to retail investors [2] - EssilorLuxottica holds ratings of A2 positive from Moody's and A stable from S&P, reflecting its solid creditworthiness [4]

Core Points - Biofrontera Inc. announced the inclusion of its propylene glycol-free formulation of Ameluz nanoemulsion gel in the FDA's Orange Book, confirming its FDA-approved status and intellectual property protection [1][2][7] - The revised formulation eliminates propylene glycol, a known allergen, enhancing patient safety while maintaining treatment efficacy [3][4] - The patent for the new formulation was issued on April 22, 2025, and is valid until December 8, 2043, preventing generic competition during this period [2][3][7] Company Overview - Biofrontera Inc. specializes in biopharmaceuticals, focusing on dermatological treatments using photodynamic therapy (PDT) [5] - The company commercializes Ameluz in combination with the RhodoLED lamp series for treating actinic keratosis and is conducting clinical trials for additional applications [5]